bluebird bio, Inc BLUE

maverick1239

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent -thalassemia; LentiGlobin for the treatment of sickle cell disease; and...

Swing_Trading_as_a_BUSINESS

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees,...

rcodonnell1

BLUE is having a classic fill the gap play. If the gap is completely filled it would be around a 33% gain. Entering a position as I message this.

ChimpCapital007 Pro

bottom feed

DigitalData

Guys, Even with news this play IS HUGE just look at the position of this chart / downtrend and where it would pivot ON A MONTHLY CHART. I am entering this trade today on on call options for 3-4 months out. Stop loss is under all time low / may even add more at that point. Solid company. Regardless of news this looks like a big reveral coming. News: 2 MINUTES AGO...

MikkyBob Premium

target 38

dread003111

BLUE

AcornWealthCorp Premium

FA Looking for Break above $31.07 Stop Signal: $27.97 Target1 : 38.43 Target 2: Momentum. Negligible insider activity.

AcornWealthCorp Premium

Entry above 30.75. Stop signal 26.43. Target 39.83

pivotanalytics Premium

BLUE has some catalysts coming up.

tencennts Premium

Weekly Chart. RSI divergence. Looks for that reversal to test its first resistance.

CobraTrader13

- PDUFA meeting this weekend - Looking for wave 5 - Undervalued - Bottom of RSI - Important buy zone Target $35 Stop Loss $26

Cidoguy Pro

Mega pump it!

Antikythera_Mechanism Pro

Fundamental Analysis: Blue Bird has suffered tremendous defeat in the stock market. Recently, a lawsuit was filed against Blue Bird, as backlash for failing to inform investors of changes with their expected timeline for completion of data release and FDA decisions. However, this coming March 27th Blue Bird is scheduled for a priority review of their joint...

decaro

Love it or hate it, it's BLUE. Anecdotal, non-scientific evidence of a serious side effect prompted a halt of a trial of a product, and the company is investigating. No one knows anything else until the company reports. End. Of. Story. There is a strong bid today, and here you can see why. BLUE has clipped long-term support and bounced nicely off of it for it's...

PeterSl Pro+

Price sold off on bad news and awaits confirmation of the claims and seems to be consolidating. Should the claims be confirmed, it is bad news for the Company. Should the news be disputed, the price is likely to reverse into the consolidation area of the previous triangle. Keep a tight stop below the consolidation area.

Swing_Trading_as_a_BUSINESS

Bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees,...

sfhenderson17

But I'm still thinking that there's something here...